Prentice Wealth Management LLC lowered its stake in shares of CVS Health Co. (NYSE:CVS) by 2.2% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 10,833 shares of the pharmacy operator’s stock after selling 247 shares during the period. CVS Health comprises about 0.5% of Prentice Wealth Management LLC’s holdings, making the stock its 22nd largest position. Prentice Wealth Management LLC’s holdings in CVS Health were worth $904,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in CVS. Clarus Group Inc. bought a new stake in CVS Health during the first quarter worth about $116,000. IndexIQ Advisors LLC boosted its stake in CVS Health by 18.8% during the first quarter. IndexIQ Advisors LLC now owns 59,660 shares of the pharmacy operator’s stock worth $4,488,000 after acquiring an additional 9,437 shares in the last quarter. Sowell Financial Services LLC boosted its stake in CVS Health by 25.5% during the first quarter. Sowell Financial Services LLC now owns 53,050 shares of the pharmacy operator’s stock worth $4,440,000 after acquiring an additional 10,768 shares in the last quarter. Meridian Wealth Advisors LLC bought a new stake in CVS Health during the first quarter worth about $424,000. Finally, Meridian Wealth Management LLC boosted its stake in CVS Health by 26.7% during the first quarter. Meridian Wealth Management LLC now owns 8,117 shares of the pharmacy operator’s stock worth $611,000 after acquiring an additional 1,712 shares in the last quarter. Institutional investors own 75.94% of the company’s stock.
CVS has been the topic of several analyst reports. Tigress Financial reiterated a “buy” rating and issued a $108.00 target price on shares of CVS Health in a research note on Friday, July 23rd. Wells Fargo & Company initiated coverage on shares of CVS Health in a research note on Monday, May 24th. They issued an “equal weight” rating and a $89.00 target price on the stock. Deutsche Bank Aktiengesellschaft upped their target price on shares of CVS Health from $95.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, August 5th. Finally, Morgan Stanley increased their price objective on shares of CVS Health from $99.00 to $114.00 and gave the company an “overweight” rating in a research report on Tuesday, August 31st. Four investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $94.89.
CVS Health (NYSE:CVS) last announced its earnings results on Tuesday, August 3rd. The pharmacy operator reported $2.42 EPS for the quarter, beating the Zacks’ consensus estimate of $2.07 by $0.35. CVS Health had a net margin of 2.59% and a return on equity of 13.81%. The business had revenue of $72.62 billion during the quarter, compared to analysts’ expectations of $70.27 billion. During the same period in the prior year, the company earned $2.62 earnings per share. The firm’s revenue was up 11.1% on a year-over-year basis. As a group, research analysts expect that CVS Health Co. will post 7.84 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Monday, August 2nd. Stockholders of record on Friday, July 23rd were paid a $0.50 dividend. The ex-dividend date of this dividend was Thursday, July 22nd. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.35%. CVS Health’s dividend payout ratio (DPR) is presently 26.67%.
In related news, Director Edward J. Ludwig bought 3,000 shares of the company’s stock in a transaction that occurred on Thursday, August 5th. The stock was purchased at an average price of $79.55 per share, for a total transaction of $238,650.00. Following the completion of the transaction, the director now owns 17,334 shares in the company, valued at $1,378,919.70. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Troyen A. Brennan sold 2,625 shares of the company’s stock in a transaction on Thursday, September 2nd. The stock was sold at an average price of $87.00, for a total transaction of $228,375.00. Following the transaction, the executive vice president now owns 140,201 shares of the company’s stock, valued at approximately $12,197,487. The disclosure for this sale can be found here. Corporate insiders own 0.69% of the company’s stock.
CVS Health Company Profile
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits, and Corporate/Other. The Pharmacy Services segment offers pharmacy benefit management solutions. The Retail or Long Term Care segment includes selling of prescription drugs and assortment of general merchandise.
Further Reading: Key terms to understand channel trading
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.